Search

Your search keyword '"Visser, Marten"' showing total 37 results
Start Over Author "Visser, Marten"
37 results on '"Visser, Marten"'

2. Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer

Author

Verdegaal, Els M E, primary, Santegoets, Saskia J, additional, Welters, Marij J P, additional, de Bruin, Linda, additional, Visser, Marten, additional, van der Minne, Caroline E, additional, de Kok, Pita M, additional, Loof, Nikki M, additional, Boekestijn, Sanne, additional, Roozen, Inge, additional, Westra, Inge M, additional, Meij, Pauline, additional, Van der Burg, Sjoerd H, additional, and Kroep, Judith R, additional

Published
2023
Full Text
View/download PDF

3. Supplementary Table S2 from Neoantigen Targetability in Progressive Advanced Melanoma

Author

van den Bulk, Jitske, primary, Verdegaal, Els M.E., primary, van der Ploeg, Manon, primary, Visser, Marten, primary, Nunes, Joana B., primary, de Ru, Arnoud H., primary, Tjokrodirijo, Rayman T.N., primary, Ijsselsteijn, Marieke E., primary, Janssen, Natasja I., primary, van der Breggen, Ruud, primary, de Bruin, Linda, primary, de Kok, Pita, primary, Janssen, George M.C., primary, Ruano, Dina, primary, Kapiteijn, Ellen H.W., primary, van Veelen, Peter A., primary, de Miranda, Noel F.C.C., primary, and van der Burg, Sjoerd H., primary

Published
2023
Full Text
View/download PDF

4. Supplementary Methods S1 from Neoantigen Targetability in Progressive Advanced Melanoma

Author

van den Bulk, Jitske, primary, Verdegaal, Els M.E., primary, van der Ploeg, Manon, primary, Visser, Marten, primary, Nunes, Joana B., primary, de Ru, Arnoud H., primary, Tjokrodirijo, Rayman T.N., primary, Ijsselsteijn, Marieke E., primary, Janssen, Natasja I., primary, van der Breggen, Ruud, primary, de Bruin, Linda, primary, de Kok, Pita, primary, Janssen, George M.C., primary, Ruano, Dina, primary, Kapiteijn, Ellen H.W., primary, van Veelen, Peter A., primary, de Miranda, Noel F.C.C., primary, and van der Burg, Sjoerd H., primary

Published
2023
Full Text
View/download PDF

5. Supplementary Figure S3 from Neoantigen Targetability in Progressive Advanced Melanoma

Author

van den Bulk, Jitske, primary, Verdegaal, Els M.E., primary, van der Ploeg, Manon, primary, Visser, Marten, primary, Nunes, Joana B., primary, de Ru, Arnoud H., primary, Tjokrodirijo, Rayman T.N., primary, Ijsselsteijn, Marieke E., primary, Janssen, Natasja I., primary, van der Breggen, Ruud, primary, de Bruin, Linda, primary, de Kok, Pita, primary, Janssen, George M.C., primary, Ruano, Dina, primary, Kapiteijn, Ellen H.W., primary, van Veelen, Peter A., primary, de Miranda, Noel F.C.C., primary, and van der Burg, Sjoerd H., primary

Published
2023
Full Text
View/download PDF

6. Data from Neoantigen Targetability in Progressive Advanced Melanoma

Author

van den Bulk, Jitske, primary, Verdegaal, Els M.E., primary, van der Ploeg, Manon, primary, Visser, Marten, primary, Nunes, Joana B., primary, de Ru, Arnoud H., primary, Tjokrodirijo, Rayman T.N., primary, Ijsselsteijn, Marieke E., primary, Janssen, Natasja I., primary, van der Breggen, Ruud, primary, de Bruin, Linda, primary, de Kok, Pita, primary, Janssen, George M.C., primary, Ruano, Dina, primary, Kapiteijn, Ellen H.W., primary, van Veelen, Peter A., primary, de Miranda, Noel F.C.C., primary, and van der Burg, Sjoerd H., primary

Published
2023
Full Text
View/download PDF

7. Neoantigen Targetability in Progressive Advanced Melanoma

Author

van den Bulk, Jitske, primary, Verdegaal, Els M.E., additional, van der Ploeg, Manon, additional, Visser, Marten, additional, Nunes, Joana B., additional, de Ru, Arnoud H., additional, Tjokrodirijo, Rayman T.N., additional, Ijsselsteijn, Marieke E., additional, Janssen, Natasja I., additional, van der Breggen, Ruud, additional, de Bruin, Linda, additional, de Kok, Pita, additional, Janssen, George M.C., additional, Ruano, Dina, additional, Kapiteijn, Ellen H.W., additional, van Veelen, Peter A., additional, de Miranda, Noel F.C.C., additional, and van der Burg, Sjoerd H., additional

Published
2023
Full Text
View/download PDF

9. Supplementary Figures 1 through 5 and supplementary Tables 1 through 3 from Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature

Author

Melief, Sara M., primary, Visconti, Valeria V., primary, Visser, Marten, primary, van Diepen, Merel, primary, Kapiteijn, Ellen H.W., primary, van den Berg, Joost H., primary, Haanen, John B.A.G., primary, Smit, Vincent T.H.B.M., primary, Oosting, Jan, primary, van der Burg, Sjoerd H., primary, and Verdegaal, Els M.E., primary

Published
2023
Full Text
View/download PDF

10. Data from Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature

Author

Melief, Sara M., primary, Visconti, Valeria V., primary, Visser, Marten, primary, van Diepen, Merel, primary, Kapiteijn, Ellen H.W., primary, van den Berg, Joost H., primary, Haanen, John B.A.G., primary, Smit, Vincent T.H.B.M., primary, Oosting, Jan, primary, van der Burg, Sjoerd H., primary, and Verdegaal, Els M.E., primary

Published
2023
Full Text
View/download PDF

11. Supplementary Figure legends from Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature

Author

Melief, Sara M., primary, Visconti, Valeria V., primary, Visser, Marten, primary, van Diepen, Merel, primary, Kapiteijn, Ellen H.W., primary, van den Berg, Joost H., primary, Haanen, John B.A.G., primary, Smit, Vincent T.H.B.M., primary, Oosting, Jan, primary, van der Burg, Sjoerd H., primary, and Verdegaal, Els M.E., primary

Published
2023
Full Text
View/download PDF

13. 343 Identification of tumor-reactive T cells targeting melanoma Dark Antigens™ validates this novel class of targets for development of immunotherapies

Author

Abbott, Rachel, primary, Hofland, Tom, additional, Hulen, Thomas, additional, Verdegaal, Elizabeth (Els), additional, Crowther, Michael, additional, Dukes, Joseph, additional, Khan, Shawez, additional, Kok, Pita de, additional, Masi, Giulia, additional, Met, Özcan, additional, Schina, Aimilia, additional, Selvadurai, Hayden, additional, Visser, Marten, additional, Ward, Katarzyna, additional, Abbott, Rachel, additional, Burg, Sjoerd van der, additional, Kassiotis, George, additional, and Svane, Inge, additional

Published
2022
Full Text
View/download PDF

14. Neoantigen landscape dynamics during human melanoma-T cell interactions

Author

Verdegaal, Els M.E., de Miranda, Noel F.C.C., Visser, Marten, Harryvan, Tom, van Buuren, Marit M., Andersen, Rikke S., Hadrup, Sine R., van der Minne, Caroline E., Schotte, Remko, Spits, Hergen, Haanen, John B.A.G., Kapiteijn, Ellen H.W., Schumacher, Ton N., and van der Burg, Sjoerd H.

Subjects
T cells -- Analysis, Rodents -- Research -- Health aspects, Immunotherapy -- Analysis, Tumor antigens -- Research -- Health aspects, Melanoma -- Research -- Health aspects, Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

Recognition of neoantigens that are formed as a consequence of DNA damage is likely to form a major driving force behind the clinical activity of cancer immunotherapies such as T-cell checkpoint blockade and adoptive T-cell therapy (1-7). Therefore, strategies to selectively enhance T-cell reactivity against genetically defined neoantigens (1,8-11) are currently under development. In mouse models, T-cell pressure can sculpt the antigenicity of tumours, resulting in the emergence of tumours that lack defined mutant antigens (12,13). However, whether the T-cell-recognized neoantigen repertoire in human cancers is constant over time is unclear. Here we analyse the stability of neoantigen-specific T-cell responses and the antigens they recognize in two patients with stage IV melanoma treated by adoptive T-cell transfer. The T-cell-recognized neoantigens can be selectively lost from the tumour cell population, either by overall reduced expression of the genes or loss of the mutant alleles. Notably, loss of expression of T-cell-recognized neoantigens was accompanied by development of neoantigen-specific T-cell reactivity in tumour-infiltrating lymphocytes. These data demonstrate the dynamic interactions between cancer cells and T cells, which suggest that T cells mediate neoantigen immunoediting, and indicate that the therapeutic induction of broad neoantigen-specific T-cell responses should be used to avoid tumour resistance., Cytotoxic [CD8.sup.+] T cells can specifically recognize and eliminate tumours (14-16). The clinical activity of antibodies against the T-cell checkpoints CTLA-4 and PD-1 underscores the notion that in many patients [...]

Published
2016
Full Text
View/download PDF

16. Enhanced antigen cross-presentation in human colorectal cancer-associated fibroblasts through upregulation of the lysosomal protease cathepsin S

Author

MMB Research line 3a, Infection & Immunity, Harryvan, Tom J., Visser, Marten, De Bruin, Linda, Plug, Léonie, Griffioen, Lisa, Mulder, Arend, Van Veelen, Peter A., Van Der Heden Van Noort, Gerbrand J., Jongsma, Marlieke L.M., Meeuwsen, Miranda H., Wiertz, Emmanuel J.H.J., Santegoets, Saskia J., Hardwick, James C.H., Van Hall, Thorbald, Neefjes, Jacques, Van Der Burg, Sjoerd H., Hawinkels, Lukas J.A.C., Verdegaal, Els M.E., MMB Research line 3a, Infection & Immunity, Harryvan, Tom J., Visser, Marten, De Bruin, Linda, Plug, Léonie, Griffioen, Lisa, Mulder, Arend, Van Veelen, Peter A., Van Der Heden Van Noort, Gerbrand J., Jongsma, Marlieke L.M., Meeuwsen, Miranda H., Wiertz, Emmanuel J.H.J., Santegoets, Saskia J., Hardwick, James C.H., Van Hall, Thorbald, Neefjes, Jacques, Van Der Burg, Sjoerd H., Hawinkels, Lukas J.A.C., and Verdegaal, Els M.E.

Published
2022

17. Enhanced antigen cross-presentation in human colorectal cancer-associated fibroblasts through upregulation of the lysosomal protease cathepsin S

Author

Harryvan, Tom J, primary, Visser, Marten, additional, de Bruin, Linda, additional, Plug, Léonie, additional, Griffioen, Lisa, additional, Mulder, Arend, additional, van Veelen, Peter A, additional, van der Heden van Noort, Gerbrand J, additional, Jongsma, Marlieke LM, additional, Meeuwsen, Miranda H, additional, Wiertz, Emmanuel JHJ, additional, Santegoets, Saskia J, additional, Hardwick, James CH, additional, Van Hall, Thorbald, additional, Neefjes, Jacques, additional, Van der Burg, Sjoerd H, additional, Hawinkels, Lukas JAC, additional, and Verdegaal, Els ME, additional

Published
2022
Full Text
View/download PDF

18. High-throughput epitope discovery reveals frequent recognition of neo-antigens by [CD4.sup.+] T cells in human melanoma

Author

Linnemann, Carsten, van Buuren, Marit M., Bies, Laura, Verdegaal, Els M.E., Schotte, Remko, Calis, Jorg J.A., Behjati, Sam, Velds, Arno, Hilkmann, Henk, el Atmioui, Dris, Visser, Marten, Stratton, Michael R., Haanen, John B.A.G., Spits, Hergen, van der Burg, Sjoerd H., and Schumacher, Ton N.M.

Subjects
T cells -- Physiological aspects -- Genetic aspects -- Research, Antigenic determinants -- Physiological aspects -- Genetic aspects -- Research, Tumor antigens -- Physiological aspects -- Genetic aspects -- Research, Melanoma -- Development and progression -- Genetic aspects -- Research, Biological sciences, Health
Abstract

Tumor-specific neo-antigens that arise as a consequence of mutations (1,2) are thought to be important for the therapeutic efficacy of cancer immunotherapies (3-5). Accumulating evidence suggests that neo-antigens may be commonly recognized by intratumoral [CD8.sup.+] T cells (3-7), but it is unclear whether neoantigen-specific [CD4.sup.+] T cells also frequently reside within human tumors. In view of the accepted role of tumor-specific [CD4.sup.+] T-cell responses in tumor control (8-10), we addressed whether neo-antigen-specific [CD4.sup.+] T-cell reactivity is a common property in human melanoma., Here, we exploit oncogene-immortalized autologous B cells to measure the occurrence of [CD4.sup.+] T-cell responses against melanoma mutanomes identified by tumor exome sequencing. Using this approach, we detected neo-antigen-reactive [CD4.sup.+] [...]

Published
2015

21. Simplified Monopalmitoyl Toll‐like Receptor 2 Ligand Mini‐UPam for Self‐Adjuvanting Neoantigen‐Based Synthetic Cancer Vaccines

Author

van den Ende, Thomas C., primary, Heuts, Jeroen M. M., additional, Gential, Geoffroy P. P., additional, Visser, Marten, additional, van de Graaff, Michel J., additional, Ho, Nataschja I., additional, Jiskoot, Wim, additional, Valentijn, A. Rob P. M., additional, Meeuwenoord, Nico J., additional, Overkleeft, Herman S., additional, Codée, Jeroen D. C., additional, van der Burg, Sjoerd H., additional, Verdegaal, Els M. E., additional, van der Marel, Gijsbert A., additional, Ossendorp, Ferry, additional, and Filippov, Dmitri V., additional

Published
2020
Full Text
View/download PDF

22. Phase I/II study protocol to assess safety and efficacy of adoptive cell therapy with anti-PD-1 plus low-dose pegylated-interferon-alpha in patients with metastatic melanoma refractory to standard of care treatments: the ACTME trial

Author

van der Kooij, Monique K, primary, Verdegaal, Els M E, additional, Visser, Marten, additional, de Bruin, Linda, additional, van der Minne, Caroline E, additional, Meij, Pauline M, additional, Roozen, Inge C F M, additional, Jonker, Mare A, additional, van den Bosch, Shelley, additional, Liefers, Gerrit-Jan, additional, Speetjens, Frank M, additional, van der Burg, Sjoerd H, additional, and Kapiteijn, Ellen, additional

Published
2020
Full Text
View/download PDF

23. Abstract CT194: Low-dose Interferon-alpha pre-conditioning and adoptive cell therapy in metastatic melanoma patients refractory to standard (immune) therapies - a phase 1/2 study

Author

van der Kooij, Monique K., primary, Verdegaal, Els M., additional, Visser, Marten, additional, van der Minne, Carolien E., additional, de Bruin, Linda, additional, Meij, Pauline, additional, van Scheltinga, Anton G. Terwisscha, additional, Welters, Marij J., additional, Santegoets, Saskia J., additional, de Miranda, Noel F., additional, Roozen, Inge C., additional, Liefers, Gerrit-Jan, additional, Kapiteijn, Ellen, additional, and van der Burg, Sjoerd H., additional

Published
2020
Full Text
View/download PDF

24. Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study

Author

Verdegaal, Els, primary, van der Kooij, Monique K, additional, Visser, Marten, additional, van der Minne, Caroline, additional, de Bruin, Linda, additional, Meij, Pauline, additional, Terwisscha van Scheltinga, Anton, additional, Welters, Marij J, additional, Santegoets, Saskia, additional, de Miranda, Noel, additional, Roozen, Inge, additional, Liefers, Gerrit Jan, additional, Kapiteijn, Ellen, additional, and van der Burg, Sjoerd H, additional

Published
2020
Full Text
View/download PDF

25. MOESM6 of Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4

Author

Bulk, Jitske Van Den, Verdegaal, Els, Ruano, Dina, Ijsselsteijn, Marieke, Visser, Marten, Breggen, Ruud Van Der, Duhen, Thomas, Ploeg, Manon Van Der, Vries, Natasja De, Oosting, Jan, Peeters, Koen, Weinberg, Andrew, Farina-Sarasqueta, Arantza, Burg, Sjoerd Van Der, and Miranda, Noel De

Subjects
education, hemic and immune systems, chemical and pharmacologic phenomena
Abstract

Additional file 6: Figure S2. Peptide reactivity screens with PBL.

Published
2019
Full Text
View/download PDF

26. Abstract B094: Successful identification of neoantigen-specific T-cell responses in low mutation burden colorectal cancers for personalized cancer vaccine development

Author

Bulk, Jitske van den, primary, Ruano, Dina, additional, Ijsselsteijn, Marieke E., additional, Visser, Marten, additional, Breggen, Ruud van der, additional, Peeters, Koen C.M.J., additional, Duhen, Thomas, additional, Duhen, Rebekka, additional, Weinberg, Andrew D, additional, Burg, Sjoerd S.H. van der, additional, Verdegaal, Els M.E., additional, and Miranda, Noel F. de, additional

Published
2019
Full Text
View/download PDF

27. Simplified Monopalmitoyl Toll‐like Receptor 2 Ligand Mini‐UPam for Self‐Adjuvanting Neoantigen‐Based Synthetic Cancer Vaccines.

Author

Ende, Thomas C., Heuts, Jeroen M. M., Gential, Geoffroy P. P., Visser, Marten, Graaff, Michel J., Ho, Nataschja I., Jiskoot, Wim, Valentijn, A. Rob P. M., Meeuwenoord, Nico J., Overkleeft, Herman S., Codée, Jeroen D. C., Burg, Sjoerd H., Verdegaal, Els M. E., Marel, Gijsbert A., Ossendorp, Ferry, and Filippov, Dmitri V.

Published
2021
Full Text
View/download PDF

28. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4(+) T cells in human melanoma (vol 21, pg 81, 2015)

Author

Linnemann, Carsten, van Buuren, Marit M., Bies, Laura, Verdegaal, Els M. E., Schotte, Remko, Calis, Jorg J. A., Behjati, Sam, Velds, Arno, Hilkmann, Henk, El Atmioui, Dris, Visser, Marten, Stratton, Michael R., Haanen, John B. A. G., Spits, Hergen, van der Burg, Sjoerd H., Schumacher, Ton N. M., Amsterdam institute for Infection and Immunity, Cell Biology and Histology, and Amsterdam Gastroenterology Endocrinology Metabolism

Published
2016

29. Corrigendum: High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

Author

Linnemann, Carsten, van Buuren, Marit M, Bies, Laura, Verdegaal, Els M E, Schotte, Remko, Calis, Jorg J A, Behjati, Sam, Velds, Arno, Hilkmann, Henk, el Atmioui, Dris, Visser, Marten, Stratton, Michael R, Haanen, John B A G, Spits, Hergen, van der Burg, Sjoerd H, and Schumacher, Ton N M

Subjects
Biological sciences, Health
Abstract

Author(s): Carsten Linnemann; Marit M van Buuren; Laura Bies; Els M E Verdegaal; Remko Schotte; Jorg J A Calis; Sam Behjati; Arno Velds; Henk Hilkmann; Dris el Atmioui; Marten Visser; [...]

Published
2016
Full Text
View/download PDF

30. Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature

Author

Melief, Sara M., primary, Visconti, Valeria V., additional, Visser, Marten, additional, van Diepen, Merel, additional, Kapiteijn, Ellen H.W., additional, van den Berg, Joost H., additional, Haanen, John B.A.G., additional, Smit, Vincent T.H.B.M., additional, Oosting, Jan, additional, van der Burg, Sjoerd H., additional, and Verdegaal, Els M.E., additional

Published
2017
Full Text
View/download PDF

31. Abstract PR11: Neo-antigen landscape dynamics during human melanoma-T cell interactions

Author

Verdegaal, Els M.E., primary, Miranda, Noel de, additional, Visser, Marten, additional, Harryvan, Tom, additional, Buuren, Marit van, additional, Andersen, Rikke, additional, Hadrup, Sine, additional, Minne, Caroline van der, additional, Schotte, Remko, additional, Spits, Hergen, additional, Haanen, John, additional, Kapiteijn, Ellen, additional, Schumacher, Ton, additional, and Burg, Sjoerd H. Van Der, additional

Published
2016
Full Text
View/download PDF

32. Erratum: Corrigendum: High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

Author

Linnemann, Carsten, primary, van Buuren, Marit M, additional, Bies, Laura, additional, Verdegaal, Els M E, additional, Schotte, Remko, additional, Calis, Jorg J A, additional, Behjati, Sam, additional, Velds, Arno, additional, Hilkmann, Henk, additional, el Atmioui, Dris, additional, Visser, Marten, additional, Stratton, Michael R, additional, Haanen, John B A G, additional, Spits, Hergen, additional, van der Burg, Sjoerd H, additional, and Schumacher, Ton N M, additional

Published
2016
Full Text
View/download PDF

34. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

Author

Linnemann, Carsten, primary, van Buuren, Marit M, additional, Bies, Laura, additional, Verdegaal, Els M E, additional, Schotte, Remko, additional, Calis, Jorg J A, additional, Behjati, Sam, additional, Velds, Arno, additional, Hilkmann, Henk, additional, Atmioui, Dris el, additional, Visser, Marten, additional, Stratton, Michael R, additional, Haanen, John B A G, additional, Spits, Hergen, additional, van der Burg, Sjoerd H, additional, and Schumacher, Ton N M, additional

Published
2014
Full Text
View/download PDF

35. Molecular Characterization of Melanoma-Derived Antigens.

Author

Walker, John M., Nickoloff, Brian J., Hood, Leroy, Visser, Marten, Velders, Markwin P., Rudolf, Michael P., and Martin Kast, W.

Abstract

In the last decade, many antigens expressed by tumors and recognized by the immune system have been identified. Melanoma was among the first tumors found to express such tumor-associated antigens, and, therefore, melanoma is currently one of the best and extensively studied tumors for which new techniques have been introduced to optimize the characterization of tumor antigens. In this chapter, we discuss the techniques used for identification of melanoma-expressed antigens recognized by cytotoxic T-lymphocytes (CTLs). In more detail, we describe in Subheading 3. the reverse immunology method. [ABSTRACT FROM AUTHOR]

Published
2001
Full Text
View/download PDF

37. Simplified Monopalmitoyl Toll-like Receptor 2 Ligand Mini-UPam for Self-Adjuvanting Neoantigen-Based Synthetic Cancer Vaccines.

Author

van den Ende TC, Heuts JMM, Gential GPP, Visser M, van de Graaff MJ, Ho NI, Jiskoot W, Valentijn ARPM, Meeuwenoord NJ, Overkleeft HS, Codée JDC, van der Burg SH, Verdegaal EME, van der Marel GA, Ossendorp F, and Filippov DV

Subjects
Antigens, Neoplasm immunology, Cancer Vaccines chemistry, Cell Line, Dendritic Cells cytology, Dendritic Cells metabolism, Drug Design, Humans, Interleukin-8 metabolism, Lipopeptides chemical synthesis, Lipopeptides chemistry, Lipopeptides immunology, Lipoylation, Lymphocyte Activation, Toll-Like Receptor 2 metabolism, Vaccines, Synthetic chemistry, Antigens, Neoplasm chemistry, Cancer Vaccines immunology, Ligands, Toll-Like Receptor 2 chemistry, Vaccines, Synthetic immunology
Abstract

Synthetic vaccines, based on antigenic peptides that comprise MHC-I and MHC-II T-cell epitopes expressed by tumors, show great promise for the immunotherapy of cancer. For optimal immunogenicity, the synthetic peptides (SPs) should be adjuvanted with suitable immunostimulatory additives. Previously, we have shown that improved immunogenicity in vivo is obtained with vaccine modalities in which an SP is covalently connected to an adjuvanting moiety, typically a ligand to Toll-like receptor 2 (TLR2). SPs were covalently attached to UPam, which is a derivative of the classic TLR2 ligand Pam 3 CysSK 4 . A disadvantage of the triply palmitoylated UPam is its high lipophilicity, which precludes universal adoption of this adjuvant for covalent modification of various antigenic peptides as it renders the synthetic vaccine insoluble in several cases. Here, we report a novel conjugatable TLR2 ligand, mini-UPam, which contains only one palmitoyl chain, rather than three, and therefore has less impact on the solubility and other physicochemical properties of a synthetic peptide. In this study, we used SPs that contain the clinically relevant neoepitopes identified in a melanoma patient who completely recovered after T-cell therapy. Homogeneous mini-UPam-SP conjugates have been prepared in good yields by stepwise solid-phase synthesis that employed a mini-UPam building block pre-prepared in solution and the standard set of Fmoc-amino acids. The immunogenicity of the novel mini-UPam-SP conjugates was demonstrated by using the cancer patient's T-cells., (© 2020 The Authors. ChemBioChem published by Wiley-VCH GmbH.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results